NCT07333430招募中1 期
A Phase 1a/1b Open-Label Study With Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Determine the Maximum Tolerated Dose (MTD)
研究概览
简要总结
A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years of age at the time of signing informed consent.
- •Voluntarily signed informed consent form.
- •Diagnosis of relapsed/refractory multiple myeloma (Parts 1a and 1b), with measurable disease at screening visit as follows:
- •Multiple Myeloma (at least one of the criteria below):
- •Serum M-protein greater or equal to 0.5 g/dL.
- •Urine M-protein greater or equal to 200 mg/24 h.
- •Serum free light chain (FLC) assay: involved FLC level greater or equal to 3 mg/dL (30 mg/L) provided serum FLC ratio is abnormal.
- •A biopsy-proven evaluable plasmacytoma*.
- •Bone marrow plasma cells > 10% of total bone marrow cells*.
- •Non secretory patient will be allowed provided they have measurable disease by PET-CT or bone marrow aspiration, as designated*.
- •Results pre-dating the Screening visit by up to 28 days may be used to establish eligibility.
- •R/R MM subjects must have been exposed to at least three prior lines of therapy including the following agents:
- •proteasome inhibitor
- •immunomodulatory (IMiDs) agent
- •anti-CD38 antibody
- •For part 1a: At least one of the following risk factors: a. Extra-medullary disease (EMD) - defined as a MM lesion that is not connected to a bone. b. previous exposure to an anti-BCMA therapy.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 -
- •Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study.
- •Recovery to ≤ Grade 2 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 3 neuropathy, and toxicities that are irreversible and not expected to interfere with study treatment or pose safety concerns, per investigator judgement.
- •Ability and willingness to adhere to the study visit schedule and all protocol requirements.
- •For subjects with relapsed multiple myeloma who have previously undergone allogenic stem cell transplantation: no evidence of graft versus host disease after cessation of any immunosuppressive therapy for at least one month before recruitment to the study.
排除标准
- •Contraindication to a study treatment/procedure or is anticipated to receive treatment/procedure that may preclude performance of study procedures.
- •Known bulky central nervous system disease.
- •Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN) and/or direct bilirubin > 4x ULN.
- •Inadequate renal function defined by estimated clearance of <20(ml/min).
- •International ratio (INR) or partial thromboplastin time (PTT) > 2 x ULN, unless on a stable dose of anticoagulant for a thromboembolic event (provided this event is not an exclusion criteria).
- •Inadequate bone marrow function defined by absolute neutrophil count (ANC) < 1000 cells/mm3, platelet count < 30,000 mm3, or hemoglobin < 8 g/dL. Subjects with absolute lymphocyte count < 300 cells/mm3 may be excluded (due to potential challenges with producing CART), per investigator judgement.
- •Left ventricular ejection fraction < 40%.
- •Ongoing treatment with chronic immunosuppressant such as cyclosporine or systemic steroids (physiological replacement doses of steroids are allowed up to 12 mg/m2/d hydrocortisone or equivalent)
- •Significant co-morbid condition or disease which in the judgment of the Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic injury, and other conditions.
- •Known human immunodeficiency virus (HIV) positive status.
- •Active Hepatitis B active infection (defined as HBS-antigen and HBV DNA positive) or Hepatitis C active infection (defined as anti-HCV and HCV RNA positive).
- •Active CMV infection.
- •Known history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within 3 months.
- •Chronic atrial fibrillation with uncontrolled heart rate.
- •Second primary malignancy that has required therapy in the last 2 years or is not in complete remission. This exclusion criterion does not exclude the following subjects: successfully treated non- metastatic basal cell or squamous cell skin carcinoma, or prostate cancer under control with hormonal therapy
- •Subjects who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation and who meet any of the following criteria:
- •Have been on a stable dose of anticoagulation for < 1 month (except for acute line insertion induced thrombosis.
- •Have had a Grade 2, 3, or 4 hemorrhage in the last 30 days
- •Are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement).
- •Pregnant or lactating women.
研究组 & 干预措施
CAR-T Naïve BCMA
Experimental
The dose escalation phase (Part 1a) will follow a 3+3 design and include up to 3 dose level cohorts. Eligible participants for Cohorts 1, 2, and 3 will receive a single (low, medium or high) dose of 80 × 106 ± 30%, 160 × 106 ± 25% and 240 × 106 ± 20% Naïve HBI0101 CART.
The expansion phase (Part 1b) will receive up to Maximum Tolerated Dose (MTD) .
干预措施: Naive HBI0101 CAR-T (Biological)
结局指标
主要结局
Determine the Maximum Tolerated Dose (MTD)
时间窗: 21 days after infusion
MTD will be determined by dose limiting toxicities
Evaluate safety of Naïve HBI0101 CART in Parts 1a and 1b
时间窗: 24 Months after infusion
Incidence of Serious Adverse Events and Adverse Events of Special Interest related to study treatment.
次要结局
- Evaluate clinical response to Naïve HBI0101 CART(24 Months after infusion)
- Evaluate Overall Survival in participants treated with Naïve HBI0101 CART(24 Months after infusion)
- Evaluate proportion of MRD negative subjects in participants treated with Naïve HBI0101 CART.(24 Months after infusion)
- Evaluate Progression-Free Survival in participants treated with Naïve HBI0101 CART(24 Months after infusion)
- Evaluate persistence of Naïve HBI0101 CART in treated participants(24 Months after infusion)
- Evaluate Duration of Response in participants treated with Naïve HBI0101 CART(24 Months after infusion)
研究者
Polina Stepensky
Prof. Polina Stepensky, Director Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Organization
Hadassah Medical Organization
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer2022-502774-17-00AstraZeneca AB95
招募中
1 期
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid TumorsColorectal CancerPancreatic CancerNon-Small Cell Lung CancerNCT07300150PAQ Therapeutics, Inc.210
招募中
1 期
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)NCT07282847AskBio Inc12
招募中
2 期
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB ligand) in Combination with Obinutuzumab and in Combination with Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma2022-502616-37-00F. Hoffmann-La Roche AG194
招募中
2 期
Study of BGB-11417 in Patients with Myeloid Malignancies2023-508881-14-00Beigene Ltd.53